CTXR
Citius Pharmaceuticals, Inc. NASDAQ Listed Oct 2, 2014$0.65
Mkt Cap $7.3M
52w Low $0.57
4.4% of range
52w High $2.48
50d MA $0.80
200d MA $1.07
P/E (TTM)
-0.2x
EV/EBITDA
-0.3x
P/B
0.1x
Debt/Equity
0.0x
ROE
-41.9%
P/FCF
-0.5x
RSI (14)
—
ATR (14)
—
Beta
1.38
50d MA
$0.80
200d MA
$1.07
Avg Volume
685.3K
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
11 Commerce Drive · Cranford, NJ 07016 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | AMC | 0.43 | -0.38 | -188.4% | 0.77 | +0.6% | -3.1% | -3.3% | -3.6% | +2.6% | -6.1% | — |
| Dec 25, 2025 | AMC | -0.24 | -0.44 | -83.5% | — | — | — | — | — | — | — | — |
| Aug 12, 2025 | AMC | -0.24 | -0.80 | -233.3% | 1.30 | -3.8% | -1.5% | +2.3% | +1.5% | +3.8% | -10.9% | — |
| May 14, 2025 | AMC | -1.08 | -1.27 | -17.6% | 0.94 | -3.0% | -11.7% | +2.5% | -9.2% | -4.1% | -7.8% | — |
| Feb 14, 2025 | AMC | -1.25 | -1.30 | -4.0% | 2.69 | -5.2% | -8.2% | -13.0% | -14.0% | -2.7% | -5.0% | — |
| Jan 3, 2025 | AMC | -0.04 | -1.75 | -4275.0% | 3.98 | -0.3% | -1.8% | +11.8% | -15.1% | -2.2% | -3.9% | — |
| Aug 12, 2024 | AMC | -1.25 | -1.50 | -20.0% | 17.28 | -6.0% | -11.7% | -3.3% | -0.6% | +2.9% | +6.2% | — |
| May 14, 2024 | AMC | -1.50 | -1.25 | +16.7% | 17.19 | -1.8% | -9.1% | +6.9% | -2.9% | +1.8% | +10.6% | — |
| Feb 14, 2024 | AMC | 3.25 | -1.50 | -146.2% | 19.30 | +0.9% | +9.1% | -5.6% | -5.7% | +2.7% | +2.6% | — |
| Dec 29, 2023 | AMC | -0.44 | -1.75 | -300.0% | 18.91 | +0.5% | +6.9% | -3.2% | -0.5% | -2.4% | +0.5% | — |
| Aug 14, 2023 | AMC | -1.50 | -1.50 | +0.0% | 23.07 | -2.5% | -6.6% | +0.8% | +2.7% | +1.3% | +0.3% | — |
| May 12, 2023 | AMC | -1.00 | -1.75 | -75.0% | 35.25 | +0.7% | -9.2% | -2.3% | -12.0% | +2.7% | +4.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11 | D. Boral Capital | Maintains | Buy → Buy | — | $0.93 | $1.02 | +9.6% | -2.3% | -4.7% | +10.9% | -8.5% | -7.9% |
| Dec 4 | D. Boral Capital | Maintains | Buy → Buy | — | $1.15 | $1.15 | +0.0% | +8.7% | -5.6% | -5.1% | +7.1% | -2.5% |
| Aug 13 | D. Boral Capital | Maintains | Buy → Buy | — | $1.30 | $1.25 | -3.8% | -1.5% | +2.3% | +1.5% | +3.8% | -10.9% |
| Jun 30 | D. Boral Capital | Maintains | Buy → Buy | — | $1.53 | $1.75 | +14.4% | +3.9% | +19.5% | +10.5% | +5.2% | -4.5% |
| Jun 10 | D. Boral Capital | Maintains | Buy → Buy | — | $1.37 | $1.00 | -27.0% | -22.6% | -4.7% | -8.9% | -4.9% | -9.7% |
| Jun 9 | D. Boral Capital | Maintains | Buy → Buy | — | $0.85 | $0.91 | +6.9% | +61.0% | -22.6% | -4.7% | -8.9% | -4.9% |
| May 23 | Maxim Group | Downgrade | Buy → Hold | — | $0.72 | $0.73 | +0.8% | -2.9% | +1.2% | -1.6% | +0.9% | -3.7% |
| May 15 | D. Boral Capital | Maintains | Buy → Buy | — | $0.94 | $0.91 | -3.0% | -11.7% | +2.5% | -9.2% | -4.1% | -7.8% |
| Feb 18 | D. Boral Capital | Maintains | Buy → Buy | — | $2.69 | $2.55 | -5.2% | -8.2% | -13.0% | -14.0% | -2.7% | -5.0% |
| Jan 7 | D. Boral Capital | Maintains | Buy → Buy | — | $3.91 | $3.92 | +0.3% | +11.8% | -15.1% | -2.2% | -3.9% | +2.0% |
| Dec 30 | D. Boral Capital | Upgrade | Hold → Buy | — | $3.68 | $3.75 | +1.9% | +6.2% | +2.3% | -3.0% | +2.6% | -1.8% |
| Nov 22 | D. Boral Capital | Downgrade | Buy → Hold | — | $4.13 | $3.35 | -18.9% | -18.9% | -0.3% | +24.3% | -13.3% | -7.8% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.23 | $11.75 | +4.6% | +7.4% | -20.1% | -14.8% | -39.1% | +12.2% |
| Nov 11 | D. Boral Capital | Maintains | Buy → Buy | — | $10.29 | $11.48 | +11.6% | +9.1% | +7.4% | -20.1% | -14.8% | -39.1% |
| Aug 19 | EF Hutton | Maintains | Buy → Buy | — | $15.08 | $14.57 | -3.4% | +6.2% | -5.8% | -0.9% | -4.1% | +3.8% |
| Aug 8 | EF Hutton | Maintains | Buy → Buy | — | $22.65 | $21.88 | -3.4% | -1.8% | -12.4% | -11.4% | -11.7% | -3.3% |
| Aug 5 | EF Hutton | Maintains | Buy → Buy | — | $22.66 | $20.03 | -11.6% | +2.9% | +9.4% | -11.2% | -1.8% | -12.4% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.39 | $16.50 | +0.7% | +6.4% | -4.6% | -4.1% | +0.4% | -1.4% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.00 | $18.50 | +8.8% | +13.5% | +9.1% | -5.6% | -5.7% | +2.7% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.02 | $24.50 | +6.4% | +8.2% | -4.5% | -3.0% | -6.6% | +0.8% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.75 | $24.41 | -1.4% | -3.6% | -4.3% | +7.0% | -5.8% | +1.0% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.75 | $28.00 | +0.9% | -0.9% | +5.5% | +6.9% | +6.5% | -2.3% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.25 | $29.25 | +0.0% | +14.5% | -1.5% | -0.8% | +4.6% | +6.6% |
| Mar 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.75 | $26.00 | +1.0% | +6.8% | +6.4% | +0.0% | +14.5% | -1.5% |
| Jan 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.25 | $37.50 | -2.0% | +1.3% | +2.6% | -2.5% | -5.2% | -2.0% |
| Jan 17 | HC Wainwright& Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 30 | Maxim Group | Maintains | Buy → Buy | — | $40.50 | $41.50 | +2.5% | +4.3% | -5.3% | -1.2% | -4.4% | +7.9% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $59.75 | $65.00 | +8.8% | +10.9% | +7.5% | -3.9% | +1.5% | -2.5% |
| May 23 | H.C. Wainwright | Maintains | Buy → Buy | — | $59.75 | $65.00 | +8.8% | +10.9% | +7.5% | -3.9% | +1.5% | -2.5% |
No insider trades available.
8-K · 1.01
!! High
Citius Pharmaceuticals Inc. Common -- 8-K 1.01: Material Agreement
Citius Pharmaceuticals raised capital through a private placement of warrants exercisable at $0.86 per share over five years, providing future upside potential if the stock appreciates significantly above the strike price.
Apr 24
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis from this filing excerpt, as it contains only standard SEC boilerplate language with no substantive company information or financial data relevant to CTXR's stock.
Apr 6
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Citius Oncology's commercial update likely signals progress toward market launches or revenue generation, which could validate CTXR's oncology strategy and potentially justify its investment in this subsidiary.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Citius Pharmaceuticals announced a commercial update for its U.S. operations, suggesting potential progress on product launches or market expansion that could drive near-term revenue growth and justify the stock's valuation.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Citius Oncology's positive Phase 1 trial results validate its oncology pipeline and could accelerate development timelines, benefiting both CTOR and parent company CTXR through reduced execution risk and potential value creation.
Mar 10
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
LYMPHIR's combination with pembrolizumab showed encouraging efficacy signals in gynecologic cancers, potentially validating a valuable combination strategy that could expand the drug's market opportunity and support future clinical development.
Mar 10
8-K · 8.01
!! High
Citius Pharmaceuticals Inc. Common -- 8-K 8.01: Material Event / Announcement
Citius Pharmaceuticals' subsidiary achieved positive Phase 1 results for LYMPHIR as a pre-treatment to CAR T therapy in relapsed/refractory DLBCL, potentially expanding the drug's commercial applications.
Mar 4
8-K · 8.01
!! High
Citius Oncology, Inc. -- 8-K 8.01: Material Event / Announcement
Citius Oncology announced positive Phase 1 safety and efficacy data for LYMPHIR combined with CD19 CAR-T therapy in relapsed/refractory DLBCL patients, potentially validating a combination treatment approach.
Mar 4
8-K
Citius Oncology, Inc. -- 8-K Filing
Citius Oncology achieved $3.9 million in December 2025 revenue from its newly launched LYMPHIR product, marking the company's first reported sales milestone.
Feb 13
8-K
Citius Pharmaceuticals Inc. Common -- 8-K Filing
Citius Pharmaceuticals risks Nasdaq delisting unless its stock price recovers above $1 by August 2026, though a potential 180-day extension exists if other listing standards are maintained.
Feb 13
Data updated apr 25, 2026 3:53am
· Source: massive.com